Wilex AG, a Munich-based biopharmaceutical company focused on antibody development, reports that Roche is discontinuing its partnership with the Wilex subsidiary Heidelberg Pharma GmbH with respect to their collaboration in the field of antibody-targeted amanitin conjugates (ATACs). The license agreement was signed in 2013 and was expanded in October 2014.

Roche has recently increased the focus of its oncology research strategy on cancer immunotherapies and deprioritized other internal and external oncology research programs accordingly.

Source: Wilex